Intrathecal baclofen for neurofibromatosis related spinal cord injury with spasticity – a case report
DOI:
https://doi.org/10.2340/jrm-cc.v7.25912Keywords:
neurofibromatosis 1, spinal cord injury, spasticity, intrathecal baclofenAbstract
This case presents a 35-year-old male with spinal predominant neurofibromatosis-1 who developed an incomplete spinal cord injury (C3 Asia C) which did not improve despite urgent decompressive surgery for multiple cervical neurofibromas. This report outlines a novel indication for intrathecal baclofen. The patient suffered from lower limb weakness with severe spasticity and required assistance of at least two for all activities. The aim of rehabilitation was to improve overall tone while focusing on independence, mobility and quality of life. After a successful trial of intrathecal baclofen, he underwent implantation of an intrathecal baclofen pump. The dose was gradually increased while he received a progressive programme of stretching and functional rehabilitation therapy. After 6 weeks, his MAS had improved to 1–2/4 and he had progressed to independent transfers, independence for most activities of daily living and was able to discharge to his family home with minimal support.
Downloads
References
Ning Z, Yang Z, Chen G, Wu W, He L, Sun Y, et al. Spinal neurofibromatosis with NF1 mutation in a classic neurofibromatosis type 1 family: A case report and literature review. Mol Genet Genomic Med 2020; 8: e1035.
https://doi.org/10.1002/mgg3.1035
Zahavi A, Geertzen JH, Middel B, Staal M, Rietman JS. Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin. J Neurol Neurosurg Psychiatry 2004; 75: 1553–1557.
https://doi.org/10.1136/jnnp.2003.014282
Huson SM, Harper PS, Compston DA. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain 1988; 111: 1355–1381.
https://doi.org/10.1093/brain/111.6.1355
Peev N, Komarov A, Osorio-Fonseca E, Zileli M. Rehabilitation of spinal cord injury: WFNS spine committee recommendations. Neuro-spine 2020; 17: 820–832.
https://doi.org/10.14245/ns.2040270.135
Ejerskov C, Raundahl M, Gregersen PA, Handrup MM. Clinical features and disease severity in patients with mosaic neurofibromatosis type 1: A single-center study and literature review. Orphanet J Rare Dis 2021; 16: 180.
https://doi.org/10.1186/s13023-021-01796-3
Nair KP, Marsden J. The management of spasticity in adults. BMJ 2014; 349: g4737.
https://doi.org/10.1136/bmj.g4737
Taricco M, Adone R, Pagliacci C, Telaro E. Pharmacological interventions for spasticity following spinal cord injury. Cochrane Database Syst Rev 2000; 2000: Cd001131.
https://doi.org/10.1002/14651858.CD001131
Nance PW. A comparison of clonidine, cyproheptadine and baclofen in spastic spinal cord injured patients. J Am Paraplegia Soc 1994; 17: 150–156.
https://doi.org/10.1080/01952307.1994.11735927
Corbett M, Frankel HL, Michaelis L. A double blind, cross-over trial of Valium in the treatment of spasticity. Paraplegia 1972; 10: 19–22.
https://doi.org/10.1038/sc.1972.4
Penn RD, Savoy SM, Corcos D, Latash M, Gottlieb G, Parke B, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989; 320: 1517–1521.
Published
How to Cite
License
Copyright (c) 2024 Carl O'Brien, Jacqui Stow, Michael O'Connor, Jacinta Morgan, Paul Murphy, Darren Roddy, Kirk Levins
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles in JRM-CC are Open Access and, unless otherwise specified, distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/). This license permits sharing, adapting, and using the material for any purpose, including commercial use, with the condition of providing full attribution to the original publication.
